Eurofarma, only Brazilian pharmaceutical among the Most Beloved Companies in Brazil
Published in: January 23, 2017
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, January 2017 – Eurofarma is among the 50 Most Beloved Companies in Brazil, according to Love Mondays’ annual ranking. The survey was exclusively based on spontaneous and secret collaborators’ assessments. The pros and the cons of working in the companies, including criteria like life quality, company’s culture, remuneration and benefits, career opportunity and general satisfaction at work.
Based on over 76 thousand assessments by professional from 80 thousand companies across the country, this was the first time Love Mondays created two separate rankings; the 50 Most Beloved Companies (comprising companies with more than 500 collaborators) and the 30 Most Beloved SMEs (comprising companies with less than 500 collaborators and startups). “It is very gratifying to know that our collaborators have assessed us in such a positive way, placing us on a privileged position among the most beloved companies in the country. This result makes very proud, particularly because it was spontaneously made by those who are part of our team, and for being the only Brazilian pharmaceutical among the highlights”, says Mikiko Inoue, Eurofarma Human Resources vice-president.
The position of each company was determined by the general satisfaction grade assigned by collaborators. The companies considered to the list of the 50 Most Beloved Companies had, at least, 50 assessments, while the list of the 30 Most Beloved SMEs received at least 15 assessments.
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br
Based on over 76 thousand assessments by professional from 80 thousand companies across the country, this was the first time Love Mondays created two separate rankings; the 50 Most Beloved Companies (comprising companies with more than 500 collaborators) and the 30 Most Beloved SMEs (comprising companies with less than 500 collaborators and startups). “It is very gratifying to know that our collaborators have assessed us in such a positive way, placing us on a privileged position among the most beloved companies in the country. This result makes very proud, particularly because it was spontaneously made by those who are part of our team, and for being the only Brazilian pharmaceutical among the highlights”, says Mikiko Inoue, Eurofarma Human Resources vice-president.
The position of each company was determined by the general satisfaction grade assigned by collaborators. The companies considered to the list of the 50 Most Beloved Companies had, at least, 50 assessments, while the list of the 30 Most Beloved SMEs received at least 15 assessments.
About Eurofarma Group
Eurofarma Group is the first Brazilian multinational pharmaceutical with 100% national capital. Acknowledged by the medical community and society for promoting access to health and quality of life with treatments at fair prices, with quality and innovation, is present in 20 countries.
With 45 years of existence and 6,500 collaborators, its position is outstanding in the segments where it operates: Medical Prescription and Over-the-counter, Generic, Hospital, Biddings, Oncology, and Services to Third Parties. Its portfolio comprises over 280 products and, in 2016, over 290 million units of medication were produced. Last year, the Group reached income of R$ 3.3 billion, 15.7% higher than in the previous year.
In 2016, with R$ 141 million in investments and its expertise and agility in Research and Development, it became the pharmaceutical with best performance in portfolio renovation, counting, today, on 176 projects in the pipeline.
For further information, access www.eurofarma.com.br
Information to Press
G&A Public Relations – Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br